C17 Stock Overview A clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Corvus Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Corvus Pharmaceuticals Historical stock prices Current Share Price US$4.77 52 Week High US$9.00 52 Week Low US$1.22 Beta 0.97 1 Month Change -45.04% 3 Month Change -1.45% 1 Year Change 228.62% 3 Year Change 100.21% 5 Year Change 21.56% Change since IPO -62.66%
Recent News & Updates
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Dec 19
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Dec 18
Corvus Pharmaceuticals, Inc. Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity Dec 05
Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis Nov 14
New major risk - Revenue and earnings growth Nov 14
Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06 See more updates
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Dec 19
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Dec 18
Corvus Pharmaceuticals, Inc. Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity Dec 05
Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis Nov 14
New major risk - Revenue and earnings growth Nov 14
Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06 Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Aug 07
Corvus Pharmaceuticals, Inc Grants FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Aug 02
Corvus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 01 Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million. May 08
Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million. May 03
Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Apr 10
Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024 Mar 14
New minor risk - Market cap size Mar 11
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases Feb 13
New major risk - Revenue and earnings growth Feb 09
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer Feb 07
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors Jan 24
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial Dec 11
New major risk - Financial position Nov 09
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases Nov 02
Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Sep 08
New major risk - Revenue and earnings growth Aug 11
New minor risk - Market cap size Aug 08
Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference Jun 30
New minor risk - Market cap size Jun 22
Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma Jun 16
Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition Dec 13
Insufficient new directors Nov 16
Corvus Pharmaceuticals, Inc. to Present Updated CPI-818 (ITK Inhibitor) Data At the American Society of Hematology Annual Meeting & Exposition Nov 04
Corvus Pharmaceuticals Receives Written Notice from the Staff of the Listing Qualifications Department of Nasdaq Oct 31
Corvus Pharmaceuticals, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer Oct 26
Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China Sep 27
Corvus Pharmaceuticals, Inc. Provides Business and Clinical Update Aug 10
Corvus Pharmaceuticals, Inc. Appoints Dr. James Rosenbaum as Senior Vice President of Research Jul 22
Insufficient new directors Apr 27
Chief Financial Officer recently bought €69k worth of stock Mar 18
Corvus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
Insufficient new directors Feb 02
Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as A Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation Dec 15
Corvus Pharmaceuticals Provides Updates on Mupadolimab Sep 24
Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations Jul 16
Independent Director Steve Krognes has left the company Jun 19
Co-Founder recently bought €83k worth of stock May 07
Co-Founder recently bought €291k worth of stock Feb 19
New 90-day high: €3.48 Feb 10
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19 Feb 05
New 90-day low: €3.16 Dec 29 Corvus Pharmaceuticals, Inc. Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. Announces Updated Data from Its Ongoing Phase 1 Study Investigating the Potential for CPI-006 Oct 06
Corvus Pharmaceuticals, Inc. Announces New Data from its Clinical Collaboration with Genentech Sep 17
Corvus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 24
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns C17 DE Biotechs DE Market 7D -32.4% -3.5% -2.0% 1Y 228.6% -14.7% 6.9%
See full shareholder returns
Return vs Market: C17 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is C17's price volatile compared to industry and market? C17 volatility C17 Average Weekly Movement 22.1% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: C17's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C17's weekly volatility has increased from 15% to 22% over the past year.
About the Company Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer.
Show more Corvus Pharmaceuticals, Inc. Fundamentals Summary How do Corvus Pharmaceuticals's earnings and revenue compare to its market cap? C17 fundamental statistics Market cap €307.30m Earnings (TTM ) -€54.47m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) C17 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$56.83m Earnings -US$56.83m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 07:15 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Corvus Pharmaceuticals, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dane Leone BTIG Li Wang Watsek Cantor Fitzgerald & Co. Vamil Divan Credit Suisse
Show 9 more analysts 
